Tag Archives: request

Verizon CEO Fires Back At ‘Uninformed’ Bernie Sanders

Verizon Communications ( VZ ) Chief Executive Lowell McAdam fired back at Democratic presidential candidate Sen. Bernie Sanders, who has criticized the phone company in support of two unions that went on strike on Wednesday. Sanders has also been at odds with General Electric ’s ( GE ) CEO Jeff Immelt. “I read with interest Jeff Immelt’s spirited response to Sen. Bernie Sanders putting GE on his hit-list of big corporations that are ‘destroying the moral fabric’ of America,” wrote McAdam in a post at LinkedIn. “In fact, I share his frustration. Verizon is in Sanders’s bull’s-eye, as well. The senator’s uninformed views are, in a word, contemptible.” The two unions represent about 39,000 Verizon landline workers, including FiOS TV and broadband services. The Communications Workers of America (CWA) and the International Brotherhood of Electrical Workers (IBEW) have been negotiating a new contract with Verizon since June. Verizon’s wireless workers are not unionized, except for roughly 100 employees. Verizon has a total workforce of nearly 178,000. Sanders has been campaigning vs. Hillary Clinton in New York, a key battleground, where Verizon is headquartered. Sanders has also accused Verizon of not paying enough taxes and asking workers to take unneeded reductions in benefits. “(Sander’s) accusation — that Verizon doesn’t pay its fair share of taxes — is just plain wrong. As our financial statements clearly show, we’ve paid more than $15.6 billion in taxes over the last two years — that’s a 35% tax rate in 2015, for anyone who’s counting,” said McAdam. “Sen. Sanders also claims that Verizon doesn’t use its profits to benefit America. Again, a look at the facts says otherwise. In the last two years, Verizon has invested some $35 billion in infrastructure.” Verizon’s wireline workers also walked out in 2000 and 2011. Verizon’s unionized workforce has shrunk from about 85,000 in 2000. “I understand that rhetoric gets heated in a presidential campaign,” McAdam continued. “I also get that big companies are an easy target for candidates looking for convenient villains for the economic distress felt by many of our citizens. But when rhetoric becomes disconnected from reality, we’ve crossed a dangerous line. We deserve better from people aspiring to be president.”

New Amazon.com Kindle E-Reader Is Smallest, Lightest Yet

After leaked images and details of the new Amazon.com ( AMZN ) e-reader — which largely proved true — the company announced the official details Wednesday. The new Kindle, called Oasis, is the most expensive, smallest and lightest offering to date. Available for preorder Wednesday at $289.99, the Oasis is 30% thinner and more than 20% lighter than the other Kindles, according to Amazon’s press release . Oasis weighs just 4.6 ounces, and it measures 3.4 millimeters — just more than a 10th of an inch — at its thinnest point. Amazon stock was up 1.5%, near 613, in midday trading on the stock market today . Amazon has an IBD Composite Rating of 78, where 99 is the highest. Shares broke out of a cup-with-handle base with a 603.34 buy point, in high volume. In its release, Amazon touted the two-battery design that the company claims will extend the battery life for “months.” The cheapest Kindle starts at $79.99 but lacks the high-resolution display and other features of the more expensive models, such as the Paperwhite — $119.99 — or the Voyage, which costs $199.99. Amazon does not break out Kindle sales. The Associated Press , citing the Association of American Publishers, reported that overall e-reader sales rose 3.8% in 2014 to $3.37 billion. Seattle-based Amazon’s content distribution — it also live streams video like Netflix ( NFLX ) does, for example — sets it apart from e-commerce players such as eBay ( EBAY ) and Wal-Mart ( WMT ).

Valeant CEO Is Brave; Clovis PT Slashed; Buy Jazz ‘Aggressively’?

Drugmakers and biotechs were on the move Tuesday as Valeant Pharmaceuticals ( VRX ) CEO J. Michael Pearson finally agreed to attend a Senate deposition, and Clovis Oncology ( CLVS ) continued to tumble after an FDA panel didn’t back an accelerated approval for a lung cancer drug. Meanwhile, Jazz Pharmaceuticals ( JAZZ ) and Medivation ( MDVN ) rallied. Valeant CEO J. Michael Pearson said Wednesday he would comply with a congressional subpoena and testify before the Senate Special Committee on Aging on April 18. He didn’t show up to a hearing last week on drug pricing. Valeant shares inched up fractionally in the stock market today despite having  plunged 4% in late trading Tuesday  after the pharmaceutical giant said creditors had submitted a default notice over delays in its annual report. Valeant has until June 11 to file its 10-K annual report or face a default. But a default seems unlikely, as the company said it would file its 10-K by April 29. Clovis shares fell 9% on continued fallout from a Food and Drug Administration panel ruling Tuesday. The independent panel didn’t recommend that Clovis’ lung cancer drug, rociletinib, receive accelerated approval and said the FDA should wait for results from a late-stage trial before making a decision. Clovis lost 5.45% on Tuesday, 4.5% on Monday and 17.7% on Friday, when FDA staff released some documents ahead of the panel meeting. A similar drug from AstraZeneca ( AZN ) received accelerated approval last year. AstraZeneca shares rose 0.6%. Mizuho lowered Clovis’ price target to 15 from 21. Credit Suisse and JPMorgan both downgraded Clovis to neutral from overweight. JPMorgan cut its price target on the stock to 15 from 42 — and down from 110 last November Medivation jumped nearly 7% on takeover buzz. Late Tuesday,  Bloomberg reported that Medivation rejected a takeover attempt from France’s Sanofi ( SNY ). Sanofi is looking to expand its cancer treatment offerings but is currently embroiled in a whistleblower suit over alleged corporate kickbacks. Sanofi shares rose 0.9%. Jazz Pharmaceuticals shares jumped nearly 5% to 146.55, climbing over its 200-day moving average after Cowen released a note saying to “add aggressively” to Jazz positions after a ruling by the U.S. Patent and Trademark Office on Tuesday. The firm has a outperform rating and 190 price target on the stock.